Effect Time of Administration of Clomiphene citrate on the Fertility of patients with Polycystic Ovary Syndrome

Clinical Trials Comparison Time of Administration of Clomiphene Citrate on Follicular Growth, Endometrial Thickness, Ovulation and Pregnancy Rates in Polycystic Ovary Syndrome Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016052125292N4

Enrollment

115

Registered

2016-09-01

Start date

2012-03-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovarian syndrome. polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: The patients was received 100 mg clomiphene for 5 days at the luteal phase immediately after completion of medroxyprogesterone. Intervention 2: Control group: The

Treatment - Drugs

Intervention group: The patients was received 100 mg clomiphene for 5 days at the luteal phase immediately after completion of medroxyprogesterone

Control group: The patients was received 100 mg clomiphene for 5 days at the third menstrual

Eligibility

Sex/Gender

Female

Age

18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with Polycystic Ovary Syndrome and undergoing Intrauterine insemination; Age 18 to 35 years; duration of infertility less than 5 years; normal hysterosalpingography and normal spermogram; No previous use of gonadotropin Exclusion criteria: Follicle-stimulating hormone base of more than or equal to 14; Ovarian pathology; There is an ovary; Absence due to male factor infertility; endometriosis; tubal obstruction

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
On Follicular Growth, Endometrial Thickness and Ovulation. Timepoint: 11 day menstrual cycle. Method of measurement: With transvaginal sonography in millimeters.	—

Secondary

Measure	Time frame
Pregnancy. Timepoint: 16 days after injection of Human Chorionic Gonadotropin. Method of measurement: B-Human Chorionic Gonadotropin test serum.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohadeseh Mahdavi

Babol University of Medical Science

mojy_rad@yahoo.com+98 11 3223 8301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026